As diagnostic biomarkers play an important role in characterising disease onset and progression, the need for blood-based markers to complement the expensive and invasive cerebrospinal fluid (CSF)-based and positron emission tomography (PET)-based biomarkers such as β-amyloid, tau, and neurofilament light chain are eagerly anticipated in dementia [88]. Here, NEFL is linked to dementia.